Literature DB >> 2883285

Effects of the pyrones, maltol and ethyl maltol, on iron absorption from the rat small intestine.

M A Barrand, B A Callingham, R C Hider.   

Abstract

The pyrones, 3-hydroxy-2-methyl-4-pyrone (maltol) and 3-hydroxy-2-ethyl-4-pyrone (ethyl maltol) chelate iron with a high affinity and selectivity. The resulting 1:3 (metal-ligand) complexes, being neutral, are able to partition readily across cell membranes and thus may facilitate iron transport across the intestinal wall. Absorption of radioactive iron (59Fe) in the presence of these pyrones was investigated in male rats 1, 2, 4 and 6 h after intraduodenal administration of a 7 micrograms dose and compared with that of 59Fe given as the sulphate, gluconate, fumarate or complexed to EDTA. Total body absorption and distribution were calculated from the 59Fe content of various tissue samples. With all the iron preparations used, blood levels of 59Fe were highest 1 h after injection whilst the 59Fe content at the major site of deposition, i.e. the bone marrow, increased up to 6 h. No 59Fe was found in the urine. Total body absorption of 59Fe was significantly higher from the pyrones than from the other four preparations. Over the dose range 0.7-700 micrograms, the proportion of 59Fe absorbed from both iron maltol and iron sulphate decreased with increasing dose. Enhanced 59Fe uptake from maltol was evident at 0.7-70 micrograms but not at 700 micrograms suggesting that use of these pyrones will not result in iron overload. Absorption of 59Fe given into the stomach was slower in onset but was sustained longer presumably via a steady delivery of iron to the duodenum from the gastric reservoir.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2883285     DOI: 10.1111/j.2042-7158.1987.tb06249.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  9 in total

1.  Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in Inflammatory Bowel Disease Patients with Iron Deficiency.

Authors:  Bernd Bokemeyer; Annette Krummenerl; Christian Maaser; Stefanie Howaldt; Michael Mroß; Nick Mallard
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-04       Impact factor: 2.441

2.  Evidence for regulatory control of iron uptake from ferric maltol across the small intestine of the rat.

Authors:  M A Barrand; B A Callingham
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

3.  Dissociation of a ferric maltol complex and its subsequent metabolism during absorption across the small intestine of the rat.

Authors:  M A Barrand; B A Callingham; P Dobbin; R C Hider
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

4.  Preventive Therapy of Experimental Colitis with Selected iron Chelators and Anti-oxidants.

Authors:  Mohsen Minaiyan; Elahe Mostaghel; Parvin Mahzouni
Journal:  Int J Prev Med       Date:  2012-03

5.  Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program.

Authors:  Christoph Gasche; Tariq Ahmad; Zsolt Tulassay; Daniel C Baumgart; Bernd Bokemeyer; Carsten Büning; Stefanie Howaldt; Andreas Stallmach
Journal:  Inflamm Bowel Dis       Date:  2015-03       Impact factor: 5.325

6.  Toxicity Studies of Ethyl Maltol and Iron Complexes in Mice.

Authors:  Zhen Li; Jieli Lu; Chonghui Wu; Quanhai Pang; Zhiwei Zhu; Ruipeng Nan; Ruochen Du; Jia Chen
Journal:  Biomed Res Int       Date:  2017-01-19       Impact factor: 3.411

7.  Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy.

Authors:  Carmen Navarrete; Francisco Carrillo-Salinas; Belén Palomares; Miriam Mecha; Carla Jiménez-Jiménez; Leyre Mestre; Ana Feliú; Maria L Bellido; Bernd L Fiebich; Giovanni Appendino; Marco A Calzado; Carmen Guaza; Eduardo Muñoz
Journal:  J Neuroinflammation       Date:  2018-03-01       Impact factor: 8.322

Review 8.  New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications.

Authors:  George J Kontoghiorghes; Annita Kolnagou; Theodora Demetriou; Marina Neocleous; Christina N Kontoghiorghe
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

9.  Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial.

Authors:  Stefanie Howaldt; Eugeni Domènech; Nicholas Martinez; Carsten Schmidt; Bernd Bokemeyer
Journal:  Inflamm Bowel Dis       Date:  2022-03-02       Impact factor: 5.325

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.